Molecular Cancer Therapeutics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Madhukar, B. V.
Right arrow Articles by Crowell, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Madhukar, B. V.
Right arrow Articles by Crowell, J.
Vol. 1, 1125-1128, October 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

Inhibition of Mitogen-activated Protein Kinase Activity of Human Lymphocytes after Oral Administration of Oltipraz 1

Burra V. Madhukar, Nikolay V. Dimitrov2, Cheryl Meyer-Leece, Margarita L. Contreras and James Crowell

Departments of Pediatrics/Human Development [B. V. M.], Medicine [N. V. D., C. M. L.], and Pharmacology and Toxicology [M. L. C.], Michigan State University, East Lansing, Michigan 48824-1317, and National Cancer Institute, Division of Cancer Prevention, Chemopreventive Agent Development Research Group, Bethesda, Maryland 20892-7149 [J. C.]

Several preclinical studies indicated that Oltipraz appears to be one of the most potent cancer chemopreventive agents. Pharmacological studies in humans provided substantial amounts of information related to doses and schedules. Oltipraz has been reported to induce phase II drug-metabolizing enzymes. However, its chemopreventive activity suggests that it may also interact with cellular processes associated with cancer cell growth and proliferation. During a clinical trial designed to monitor eventual Oltipraz toxicity in high-risk population for development of lung cancer, we performed companion studies related to cell proliferation. Human lymphocytes were chosen as surrogate tissue to assess the in vivo effects of Oltipraz on cell signaling pathways involved in cell proliferation. The results of this study demonstrate that Oltipraz markedly inhibited the activation state of the extracellular signal-regulated kinases of the mitogen-activated protein kinase family of kinases in lymphocytes of subjects treated with two different doses and schedules of Oltipraz. Individual variations were observed that were not related to Oltipraz dosing or schedule of administration. The results from this study indicate that lymphocytes could be used as surrogate tissue for the development of biomarkers for studies of anticarcinogenic agents.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.